immunotherapies

This is the latest episode of the free DDW podcast, “The next steps in the fight against cancer”. It covers two articles written for Volume 22, Issue 4 – Fall 2021 of DDW. They are called “Accelerating research: the path forward for treating rare cancers” and “Inside combination immunotherapies for cancer”. RareCan is a new […]

By Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences. Although immunotherapy has revolutionised cancer therapy, the effectiveness of currently available immunotherapies varies significantly across patients and treatment types. As a result, researchers are striving to continually improve immuno-oncology approaches using the patient’s own immune cells to combat tumours. Humanised immune system (HIS) mouse models that […]

As public awareness about vaccines continues, there’s a population of people that is at increased risk of infection – the immunocompromised. Dr. Jeffery Stein, CEO of Cidara and an expert in viral diseases is passionate about the progress he’s seen with drug-Fc conjugate (DFCs), a new class of immunotherapeutic antivirals, which act directly on the […]

Suchita Gupta examines the immunochemistry reagents market post Covid-19. Immunohistochemistry (IHC) is referred to as the study of a branch of chemistry including the study of various components and functions of the immune system with the application of antigen & antibodies as chemical reagents. It is a technique that combines anatomy, physiology, immunology and biochemistry.  […]

News round-up by DDW’s Reece Armstrong for 23-27 May   UK investment plans, company appointments to drive strategy, and digital health platforms are some of the themes of this week’s news round-up.    New £20m fund launches to support North West life sciences  A new £20 million fund has been launched in the Northwest of England to […]

DDW Deputy Editor Reece Armstrong speaks to Professor Frederic Triebel, CSO of Immutep about the approval of Bristol Myers Squibb’s LAG-3 antibody and why it’s causing so much excitement in the sector.    Recently, the Food and Drug Administration (FDA) approved the first combination therapy to block the immune checkpoint receptor protein LAG-3 – a move which is […]

Ilya Pharma, a clinical stage immunotherapy company, has closed a €8.5 million funding round, which will be used to advance the company’s portfolio of three first-in-class immunotherapies for skin and mucosal diseases.   The portfolio   The active portfolio includes ILP100-Topical for treatment surgical wounds in diabetic, prediabetic and obese patients especially at risk, ILP100-Topical for diabetic […]

Chimeric Antigen Receptor or CAR-T cells, a new form of immunotherapy with genetically engineered immune system cells, has been approved for the treatment of multiple myeloma, a type of blood cancer.  Context  In a case study published in Nature Medicine, Sinai scientists reported a previously unknown neurological side effect resembling symptoms Parkinson’s Disease in a patient […]

Listen to this article on the DDW Podcast: Combination immunotherapies are one of the most exciting advanced therapy medicinal products (ATMP) being developed, with incredible potential for treating cancer, says Panagiotis Parsonidis, a molecular biologist and lead researcher at RGCC. DDW speaks to him about VAXO-Q-RE developments, a combination immunotherapy that will soon enter clinical trials.  VAXO-Q-RE is […]

eTheRNA immunotherapies, a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, has opened a subsidiary, eTheRNA Asia, with offices located in the Sheung Wan area of Hong Kong. The Asia-Pacific region is growing in importance in the global healthcare sector and this new subsidiary will serve as a focus for […]